WWWen-Xin Wei

Wen-Xin Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wen-Xin Wei has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Fan

    The Hospital Affiliated to Shanxi University of Chinese Medicine, Xianyang, China

    1 shared publication
  • Feng Gao

    Department of Orthopedics and Traumatology, Beijing Jishuitan Hospital, Capital Medical University, 31 Xinjiekou East Road, Xicheng District, Beijing 100035, China

    1 shared publication
  • Jinlong Chen

    State Key Laboratory of Oral Diseases & National Centre for Stomatology & National Clinical Research Center for Oral Diseases & Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology Sichuan University Chengdu Sichuan China

    1 shared publication
  • Tian Li

    Tianjin Key Laboratory of Acute Abdomen Disease-Associated Organ Injury and ITCWM Repair, Institute of Integrative Medicine of Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin Medical University, Tianjin, China

    1 shared publication
  • Yi-Hao Jiang

    School of Resources, Environment and Chemical Engineering, Nanchang University, Nanchang, Jiangxi, China

    1 shared publication
  • Yihao Jiang

    School of Chemistry and Chemical Engineering, Nanchang University, Nanchang, China.

    1 shared publication

Latest Publications

  • Open Access

    SIRT3/6: an amazing challenge and opportunity in the fight against fibrosis and aging

    by Wenxin Wei, Tian Li, Jinlong Chen, Zhen Fan, Feng Gao, Zhibiao Yu, Yihao Jiang

    Fibrosis is a typical aging-related pathological process involving almost all organs, including the heart, kidney, liver, lung, and skin. Fibrogenesis is a highly orchestrated process defined by sequences of cellular response and molecular signals mechanisms underlying the disease. In pathophysiologic conditions associated with organ fibrosis, a variety of injurious stimuli such as metabolic disorders, epigenetic changes, and aging may induce the progression of fibrosis. Sirtuins protein is a kind of deacetylase which can regulate cell metabolism and participate in a variety of cell physiological functions. In this review, we outline our current understanding of common principles of fibrogenic mechanisms and the functional role of SIRT3/6 in aging-related fibrosis. In addition, sequences of novel protective strategies have been identified directly or indirectly according to these mechanisms. Here, we highlight the role and biological function of SIRT3/6 focus on aging fibrosis, as well as their inhibitors and activators as novel preventative or therapeutic interventions for aging-related tissue fibrosis. Graphical abstract


  • Open Access

    To Investigate the Clinical Efficacy and Potential Mechanism of Tongxinluo Capsules in Preventing Coronary Restenosis Based on Meta‐Analysis and Network Pharmacology Analysis

    by Wen-Xin Wei, Yi-Hao Jiang

    Objective. The aim of this study is to evaluate the clinical efficacy of Tongxinluo capsules in preventing coronary restenosis based on meta‐analysis and network pharmacology research methods and to preliminarily explore its intervention mechanism. Methods. First, through meta‐analysis, we comprehensively searched databases such as CNKI, Wanfang, PubMed, the Cochrane Library, and Web of Science to find out the randomized controlled trials of Tongxinluo capsules in the treatment of coronary restenosis until February, 2022. According to the Cochrane Library, risk bias assessment tools were used to evaluate the included literature and Review Manager 5.2 software was used to conduct statistical analysis of the included studies. Then, based on network pharmacology, through TCMSP database and BATMAN‐TCM database screening, the chemical components of Tongxinluo capsules and their related effects, symptom, and common targets were analyzed. String net was used to construct protein‐protein interaction (PPI) network, and R3.6.1 software was used to carry out GO biological process enrichment analysis and KEGG signaling pathway enrichment analysis to clarify key pathways. Results. The meta‐analysis finally included 10 RCTs with a total of 1318 subjects. Meta‐analysis results showed that Tongxinluo capsules combined with conventional cardiovascular drugs could significantly improve the clinical efficacy of preventing in‐stent restenosis and the clinical efficacy of preventing angina pectoris. There was no significant difference in the clinical efficacy of preventing myocardial infarction. Network pharmacology obtained a total of 101 chemical components and 149 targets through the online database. The results of network analysis showed that the targets were mainly involved in receptor ligand activity, carboxylic acid binding, steroid hormone receptor activity, and other related action pathways and were also involved in AGE‐RAGE signaling pathway, cell senescence signaling pathway, and other related pathways. Conclusion. Tongxinluo capsules combined with conventional cardiovascular drugs can improve the clinical efficacy of preventing in‐stent restenosis and angina pectoris and have a significant effect on reducing inflammatory factors. The comprehensive result of the effect is mainly through the participation of receptor ligand activity, carboxylic acid binding, steroid hormone receptor activity, and other ways to achieve the purpose of treating coronary restenosis.